Mycotopia Therapies, Inc. TPIA
We take great care to ensure that the data presented and summarized in this overview for Mycotopia Therapies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TPIA
Top Purchases
Top Sells
About TPIA
Mycotopia Therapies, Inc. focuses on psychedelics for the treatment of mental health issues. It provides psychedelic therapies for the treatment of post-traumatic stress disorder, severe anxiety, depression, palliative care, and serotonin syndrome. The company is based in Aventura, Florida. Mycotopia Therapies, Inc. is a subsidiary of EHAVE, Inc.
Insider Transactions at TPIA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 25
2025
|
Benjamin Nathaniel Kaplan CEO |
BUY
Grant, award, or other acquisition
|
Direct |
75,000,000
+44.05%
|
-
|
|
Dec 13
2024
|
Mark Croskery Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000,000
+49.96%
|
$0
$0.01 P/Share
|
|
Dec 13
2024
|
Benjamin Kaplan CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000,000
+49.69%
|
$0
$0.01 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 105M shares |
|---|